Literature DB >> 11232007

Loss of heterozygosity at the RET protooncogene locus in a case of multiple endocrine neoplasia type 2A.

L Quadro1, O Fattoruso, M P Cosma, U Verga, A Porcellini, A Libroia, V Colantuoni.   

Abstract

We describe a patient affected by multiple endocrine neoplasia type 2A (MEN 2A) bearing a heterozygous germline mutation (Cys(634)Arg) in exon 11 and an additional somatic mutation of the RET protooncogene. A large intragenic deletion, spanning exon 4 to exon 16, affected the normal allele and was detected by quantitative PCR, Southern blot analysis, and screening of several polymorphic markers. This deletion causes RET loss of heterozygosity exclusively in the metastasis, thus suggesting a role for this second mutational event in tumor progression. No additional mutations were found in the other exons analyzed. We provide the first evidence that RET, a dominant oncogene, is affected by a germline mutation and by an additional somatic deletion of the wild-type allele. This unusual genetic profile may be related to the clinical course and very poor outcome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11232007     DOI: 10.1210/jcem.86.1.7144

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Does a somatic deletion in RET clarify the sporadic nature of medullary thyroid carcinoma?

Authors:  O Gimm; D J Marsh
Journal:  J Endocrinol Invest       Date:  2003-04       Impact factor: 4.256

Review 2.  Molecular pathogenesis of MEN2-associated tumors.

Authors:  Christian A Koch
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

3.  Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome.

Authors:  M Poturnajova; V Altanerova; L Kostalova; J Breza; C Altaner
Journal:  J Mol Med (Berl)       Date:  2004-12-09       Impact factor: 4.599

4.  Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.

Authors:  Kasmintan A Schrader; Donavan T Cheng; Vijai Joseph; Meera Prasad; Michael Walsh; Ahmet Zehir; Ai Ni; Tinu Thomas; Ryma Benayed; Asad Ashraf; Annie Lincoln; Maria Arcila; Zsofia Stadler; David Solit; David M Hyman; David Hyman; Liying Zhang; David Klimstra; Marc Ladanyi; Kenneth Offit; Michael Berger; Mark Robson
Journal:  JAMA Oncol       Date:  2016-01       Impact factor: 31.777

5.  Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma.

Authors:  Christian A Koch; Frederieke M Brouwers; Alexander O Vortmeyer; Andrea Tannapfel; Steven K Libutti; Zhengping Zhuang; Karel Pacak; Hartmut P H Neumann; Ralf Paschke
Journal:  BMC Cancer       Date:  2006-05-17       Impact factor: 4.430

6.  Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET.

Authors:  Margarita Raygada; Mark Raffeld; Andrew Bernstein; Markku Miettinen; John Glod; Marybeth S Hughes; Karlyne Reilly; Brigitte Widemann; Jaydira Del Rivero
Journal:  Am J Med Genet A       Date:  2021-02-21       Impact factor: 2.802

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.